UnknownNCT03210935
French National Database of Rare Dermatological Cancers
Studying Cutaneous neuroendocrine carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Lille
- Principal Investigator
- Laurent MORTIER, MD,PhDUniversity Hospital, Lille
- Enrollment
- 9000 enrolled
- Eligibility
- All sexes
- Timeline
- 2015 – 2025
Study locations (30)
- CHU Amiens Picardie, Amiens, France
- CHU Angers, Angers, France
- CH Annecy Gennevois, Annecy, France
- CHU Besançon, Besançon, France
- CHU Avicenne, Bobigny, France
- CHU Ambroise Paré, Boulogne-Billancourt, France
- CHU de Brest, Brest, France
- CHU de Caen, Caen, France
- CHU de Clermont Ferrand, Clermont-Ferrand, France
- CHU Bocage, Dijon, France
- CHU de Grenoble, Grenoble, France
- CH Le Mans, Le Mans, France
- CHU de Limoges, Limoges, France
- Centre Léon Bérard, Lyon, France
- Hôpital La Timone, Marseille, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03210935 on ClinicalTrials.govOther trials for Cutaneous neuroendocrine carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07302347A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07288073TIL Therapy in cSCC and MCCKaram Khaddour, MD, MS
- RECRUITINGNCT07215988Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational StudyOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE1NCT06940440IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)TuHURA Biosciences, Inc.
- RECRUITINGPHASE2, PHASE3NCT06947928Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaTuHURA Biosciences, Inc.
- RECRUITINGNCT06780475Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT07080242Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsSystImmune Inc.
- RECRUITINGNCT06608511Liquid Biomarker Study in Melanoma and Non-Melanoma Skin CancersUniversity of Wisconsin, Madison